Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen Idec 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 3Q

3Q Revenues: $1.2 billion (+5%)

3Q Earnings: $254 million (-8%)

YTD Revenues: $3.5 billion (+8%)

YTD Earnings: $765.0 million (+15%)

Comments: Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million. Rituxan revenues were down 9% to $258 million. Royalty revenues were $36 million in the quarter (+3%). Biogen sells Tysabri through a partnership with Elan Corp. and markets Rituxan with Roche’s Genentech division.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters